New Delhi: Bharat Biotech’s intranasal covid-19 vaccine–iNCOVACC (BBV154)–will be available for ₹325 per dose at government hospitals, and for ₹800 in private settings, the pharma major said on Tuesday. iNCOVACC will also be available on the CoWin platform and will be rolled out in the fourth week of January.
Last week, Bharat Biotech’s intranasal vaccine was approved by the Union health ministry as a booster dose for those aged 18 years and above.
According to the company, iNCOVACC is the world’s first intranasal vaccine for covid-19 to have received approval for a primary two-dose schedule, and as a heterologous booster dose.
Clinical trials were conducted to evaluate iNCOVACC as a primary dose, and as heterologous booster dose for subjects who have previously received two doses of the two commonly administered Covid-19 vaccines in India.
As a needle-less vaccination, Bharat Biotech’s iNCOVACC️ will be India’s first such booster dose.